Analysts are closely watching Thermo Fisher Scientific Inc. (TMO), with William Blair and Stifel reiterating Buy ratings and setting price targets indicating significant upside potential. The company’s strong performance, particularly its exposure to the biopharma segment, is a key driver for bullish sentiment. Thermo Fisher is also expected to benefit from high-single-digit EPS growth, including contributions from the Clario acquisition.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why Analysts Are Closely Watching Thermo Fisher Scientific Inc. (TMO)
Analysts are closely watching Thermo Fisher Scientific Inc. (TMO), with William Blair and Stifel reiterating Buy ratings and setting price targets indicating significant upside potential. The company’s strong performance, particularly its exposure to the biopharma segment, is a key driver for bullish sentiment. Thermo Fisher is also expected to benefit from high-single-digit EPS growth, including contributions from the Clario acquisition.